Drug Profile
HL 301
Alternative Names: HL301Latest Information Update: 06 Apr 2021
Price :
$50
*
At a glance
- Originator Hanlim Pharmaceutical
- Developer Hanlim Pharmaceutical; HL Genomics
- Class Antibronchitics; Herbal medicines; Traditional Chinese medicine
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bronchitis
Most Recent Events
- 06 Apr 2021 No development reported - Phase-III for Bronchitis in South Korea (PO)
- 17 Nov 2020 Hanlim Pharmaceutical plans a phase II trial for Radiation injuries in South Korea in November 2020 (PO) (NCT04632342)
- 21 Sep 2018 Hanlim Pharm completes a phase III trial for Bronchitis in South Korea (PO, Tablet) (NCT03654196)